Talaris Therapeutics Wins 2019 “Big Idea” Xconomy Award

BOSTON, Mass., and LOUISVILLE, Ky., September 18, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, has been named the “Big Idea” winner of the 2019 Xconomy Awards.

The Big Idea award honors a “bold, unique idea” that is making “a big impact” in healthcare or life sciences. Xconomy’s esteemed panel of judgesconferred this distinction to Talaris in recognition of the company’s vision of safely retraining the immune system to tolerate a donated organ without the need for lifelong drug therapy. Results of Talaris’ Phase 2 trialannounced earlier this year show that the company’s lead candidate, FCR001, can durably free a significant proportion of living donor kidney transplant recipients from all chronic immunosuppression by about 12 months after their transplant, without rejection of their transplanted organ.

“We’re gratified to have received this recognition honoring the visionary research of our founder, Dr. Suzanne Ildstad, and our team’s passion and dedication to improving the lives of organ transplant recipients,” said Talaris’ Chief Executive Officer Scott Requadt. “As we prepare to begin a Phase 3 clinical trial of our therapy in the coming months, we are eager to continue to leverage the ‘big idea’ underlying our therapy to reshape standards of care in transplant medicine and severe auto-immune disease.”

Talaris Therapeutics

Talaris Therapeutics, Inc. is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Talaris was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville, KY. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA and maintains corporate offices in Boston, MA and Louisville, KY. www.TalarisTx.com.

Media Contact

Lisa Raffensperger
Ten Bridge Communications
(617) 903-8783